Adaptogenics Health Corp. Announces Effective Date of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") is pleased to announce that the Canadian Securities Exchange (the "CSE") has approved the consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every four (4) pre-Consolidation Common Shares. The Consolidation will become effective at the...
2026-07-14 5:02 PM EDT
Adaptogenics Health Corp. Announces Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that it intends to consolidate the common shares of the Company on a four-to-one basis (the "Consolidation"). The Company has 16,397,701 Common Shars outstanding, and if completed, the proposed Consolidation would reduce the issued and outstanding Common Shares to approximately 4,099,425 Common Shares. Subject to review and acceptance by the Canadian...
2026-07-08 7:11 PM EDT
Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2026) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company") announces that its board of directors has initiated a strategic review to evaluate potential business opportunities within the broader health and wellness sector. As part of this review, the Company's board of directors and senior management are examining a range of potential strategic initiatives, which may include prospective business line transitions,...
2026-05-01 2:40 PM EDT
Adaptogenics Health Corp. Signs Letter of Intent with Pulmonem Inc. for Proposed Reverse Takeover Transaction
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2024) - Adaptogenics Health Corp. (CSE: ADPT) ("Adaptogenics", the "Company" or the "Issuer") is pleased to announce it has entered into a non-binding letter of intent (the "LOI"), dated November 7, 2024, to acquire all of the issued and outstanding shares of Pulmonem Inc. (the "Target"), which is arm's length to the Company, resulting in a proposed reverse takeover of the Issuer (the "Transaction"). On closing of the Transaction (the...
2024-11-08 3:02 PM EST